Steve Harr, CEO of Sana Biotechnology, shares an update on Sana’s clinical pipeline including its work on blood cancers, and its additional focus on curing Type 1 diabetes. More from Flagship @ JPM2023 here.
Related Companies
- Sana Biotechnology Founded: 2018
